FACULTY PROFILE
Dr.Lomada Dakshayani
Assistant Professor
Department of Genetics and Genomics
08562-225419
dlomada@yahoo.com, dlomada@yogivemanauniversity.ac.in






Qualification :
Ph.D. in Biochemistry (Osmania University).
PDF experience :
- Post doctoral fellow (2001-08) U T MD Anderson Cancer Center, USA.
- Senior Research associate (2008-09) The Scripps Research Institute, USA
Area/s of research interests :
Nanoparticles mediated immune responses, Developmental and tumor immunology Aging and AIDS .
Projects undertaken :
S.NO Title of the project Duration Funding agency Amount (Rs)
1 Molecular signaling during thymus involution and its application for the prevention of age associated diseases and cancer (PI) 2018-20 DST 44,59,386.00
2 Molecular mechanism involved in the development of skin gamma delata T cells (PI) 2012-15 DST 21,55,000.00
3 Role of nuclear receptor farnesoid X receptor on airway inflammation and remodeling (Co-PI) 2011-15 DBT 39,00,000.00
4 Cross-talk between plasmacytoid dendritic cells and regulatory T cells in ovarian cancer using mouse model (PI) 2012-15 CSIR 22,00,000.00
Achievements/Awards :
• Raman Fellowship for Post Doctoral Research in USA for the Year 2014-15
• DST Young Scientist Award 2011
• UT MDACC Employee service award, USA 2006
• Research Fellowship of Graduate Aptitude Test in Engineering, Govt. of India 1995-2000.
Memberships :
1. Life member, Indian Immunological Society
2. Life member, Indian Association for Cancer Research
3. Life member, The Indian Science Congress Association
Administrative Positions held
1. Co-Ordinator, Department of Genetics & Genomics, 2010- 2012.
2. Women's Hostel warden Oct 2013-present
3. BOS Member, Department of Genetics & Genomics, Oct-2013-present
4.BOS Member, Chaitanya Degree College (Autonomous) Warangal, 2015-present.
Significant paper publications:
1. Latha TS, Madhava C Reddy,Durbaka PV, Muthukonda SV, and Dakshayani Lomada. Immuomodulatory properties of titanium dioxide nanostructural materials. Indian J Pharmacol. 49: 458-64, 2018. IF: 0.63
2. Latha TS, Madhava C Reddy, Muthukonda SV, and Dakshayani Lomada. In vitro and In vivo evaluation of anti-cancer activity of TiO2 nanomaterials. Mater Sci Eng C Mater Biol Appl. 2017, 78: 969-977. IF: 4.16
3. Zhu F, Willette-Brown J, Song NY, Dakshayani Lomada, Song Y, Xue L, Gray Z, Zhao Z, Davis SR, Sun Z, Zhang P, Wu X, Zhan Q, Richie ER, Hu Y. Autoreactive T cells and Chronic fungal infection drive esophageal carcinogenesis. Cell Host Microbe. 21:478-493,2017. IF: 12.5
4. Lomada Dakshayani, Jain M, Bolner M, Reeh KAG, Kang R, Reddy MC, DiGiovanni J, Richie ER. Stat3 Signaling promotes survival and maintenance of medullary thymic epithelial cells. PLoS Genet. 2016 12(1):e1005777.IF: 6.66
5. Latha TS, Dakshayani Lomada , Dharani PK, Muthukonda SV, Reddy MC .Ti-O based nanomaterials ameliorate experimental autoimmune encephalomyelitis and collagen-induced arthritis.RSC Adv., 6, 8870-8880, 2016.IF: 3.28
6. Latha TS, Reddy MC, Durbaka PV, Rachamallu A, Pallu R and Lomada Dakshayani. T cell-mediated immune responses in disease and therapy. Front Immunol. 5:571.2014 IF: 5.69
7. Latha TS, Panati K, Gowd DS, Reddy MC and Lomada Dakshayani. Ovarian Cancer Biology and Immunotherapy. Int Rev Immunol. 33(5) 428-440, 2014. IF: 4.43
8. Lomada Dakshayani, Liu B, Coghlan L, Hu Y, Richie ER. Thymus medulla formation and central tolerance are restored in IKKalpha-/- mice that express an IKKalpha transgene in keratin 5+ thymic epithelial cells. J Immunol. 178: 829-837, 2007.IF:4.98
9. Manuri PR, Nehete B, Nehete NP, Reisenauer R, Gambhira R, Lomada Dakshayani, Chopra AK, and Sastry KJ. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine. 25: 3302-3310, 2007. IF:3.41
10. Lomada Dakshayani, Gambhira R, Nehete PN, Guhad FA, Chopra AK, Peterson JW, Sastry KJ. A two-codon mutant of cholera toxin lacking ADP-ribosylating activity functions as an effective adjuvant for eliciting mucosal and systemic cellular immune responses to peptide antigens. Vaccine. 23(4): 555-565, 2004. IF:3.41